局部晚期鼻癌的最佳组合治疗:系统性审查和贝叶斯网络元分析
Zexin Song1, Likai Chen1, Qi Zhang2
1School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
American journal of otolaryngology
|June 27, 2025
概括
对于局部发达的鼻癌 (LA-NPC),诱导化学疗法 (IC) 加上与抗EGFR疗法并发化学放射疗法 (CCRT) 显示出更好的生存率. IC + CCRT + 辅助化疗 (AC) + 抗EGFR的组合为LA-NPC提供了最好的结果.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 医学瘤学 医学瘤学
背景情况:
- 局部先进的鼻癌 (LA-NPC) 是一个重大的治疗挑战.
- 优化治疗策略对于改善患者存活率和减少不良事件至关重要.
研究的目的:
- 系统地确定LA-NPC的最佳治疗策略.
- 为了比较LA-NPC的各种治疗方案的疗效和安全性.
主要方法:
- 在PubMed,科学网络,Embase和Cochrane图书馆进行了系统的文献搜索,截至2024年5月24日.
- 使用Cochrane工具2.0评估了偏差风险;使用Stata 16.0和R 4.4.0.0进行了统计分析.
- 使用累积排名下的表面 (SUCRA) 分析来对治疗疗效进行排名.
主要成果:
- 该分析包括了46项研究,涉及15667名患者.
- 与CCRT+辅助化疗 (AC) 相比,诱导化疗 (IC) +并发化疗 (CCRT) +表皮生长因子受体抗体 (抗EGFR) 改善了整体存活率 (OS).
- IC + CCRT + AC + anti-EGFR组合显示了OS (87.49%) 和远程无转移生存率 (DMFS) (85.90%) 的最高排名.
结论:
- IC + CCRT + AC + 抗EGFR组合疗法在LA-NPC中显著改善OS,DMFS和局部无故障生存率 (LRFS).
- 虽然有希望,但需要进一步的精心设计的研究来验证这些发现,特别是关于免疫治疗和向治疗.
- CCRT + 抗EGFR组合在无进展生存期 (PFS) 中表现出高疗效,IC + RT具有最低的3-4级不良反应 (AE).
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458


